Total Payments
$1.8M
2024 Payments
$238,917
Companies
27
Transactions
1,482
Medicare Patients
467
Medicare Billing
$62,901
Payment Breakdown by Category
Other$1.4M (77.2%)
Travel$218,365 (12.3%)
Consulting$107,240 (6.1%)
Research$45,001 (2.5%)
Food & Beverage$32,638 (1.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.4M | 366 | 77.1% |
| Travel and Lodging | $218,365 | 529 | 12.3% |
| Consulting Fee | $107,240 | 27 | 6.1% |
| Unspecified | $45,001 | 41 | 2.5% |
| Food and Beverage | $32,638 | 517 | 1.8% |
| Honoraria | $1,500 | 1 | 0.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $900.00 | 1 | 0.1% |
Payments by Type
General
$1.7M
1,441 transactions
Research
$45,001
41 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $301,259 | 292 | $0 (2024) |
| GENZYME CORPORATION | $263,177 | 181 | $0 (2024) |
| Celgene Corporation | $262,277 | 232 | $0 (2024) |
| Janssen Biotech, Inc. | $215,373 | 204 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $187,602 | 145 | $0 (2022) |
| Janssen Scientific Affairs, LLC | $128,421 | 100 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $101,715 | 103 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $101,050 | 76 | $0 (2023) |
| PFIZER INC. | $93,811 | 51 | $0 (2024) |
| Millennium Pharmaceuticals, Inc. | $43,358 | 38 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $238,917 | 161 | PFIZER INC. ($90,055) |
| 2023 | $142,292 | 132 | GENZYME CORPORATION ($74,663) |
| 2022 | $258,519 | 215 | E.R. Squibb & Sons, L.L.C. ($76,595) |
| 2021 | $171,369 | 115 | GENZYME CORPORATION ($51,861) |
| 2020 | $85,581 | 83 | Janssen Biotech, Inc. ($27,267) |
| 2019 | $274,413 | 237 | Janssen Biotech, Inc. ($112,316) |
| 2018 | $343,637 | 313 | Janssen Scientific Affairs, LLC ($96,957) |
| 2017 | $256,514 | 226 | Celgene Corporation ($121,076) |
All Payment Transactions
1,482 individual payment records from CMS Open Payments — Page 1 of 60
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/04/2024 | PFIZER INC. | ELREXFIO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,500.00 | General |
| Category: ONCOLOGY | ||||||
| 11/28/2024 | PFIZER INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,000.00 | General |
| 11/28/2024 | PFIZER INC. | ELREXFIO (Drug) | Travel and Lodging | In-kind items and services | $450.02 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2024 | PFIZER INC. | ELREXFIO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,750.00 | General |
| Category: ONCOLOGY | ||||||
| 11/25/2024 | PFIZER INC. | ELREXFIO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,775.00 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | PFIZER INC. | ELREXFIO (Drug) | Travel and Lodging | In-kind items and services | $100.00 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | PFIZER INC. | ELREXFIO (Drug) | Food and Beverage | In-kind items and services | $74.00 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | PFIZER INC. | ELREXFIO (Drug) | Travel and Lodging | In-kind items and services | $61.60 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | PFIZER INC. | ELREXFIO (Drug) | Travel and Lodging | In-kind items and services | $51.00 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | PFIZER INC. | ELREXFIO (Drug) | Travel and Lodging | In-kind items and services | $48.50 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | PFIZER INC. | ELREXFIO (Drug) | Food and Beverage | In-kind items and services | $46.92 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | PFIZER INC. | ELREXFIO (Drug) | Food and Beverage | In-kind items and services | $46.49 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | PFIZER INC. | ELREXFIO (Drug) | Travel and Lodging | In-kind items and services | $254.24 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | PFIZER INC. | ELREXFIO (Drug) | Food and Beverage | In-kind items and services | $102.08 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $8,726.00 | General |
| Category: Oncology | ||||||
| 11/14/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Travel and Lodging | Cash or cash equivalent | $224.45 | General |
| Category: Oncology | ||||||
| 11/14/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Travel and Lodging | In-kind items and services | $180.96 | General |
| Category: Oncology | ||||||
| 11/14/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $117.15 | General |
| Category: Oncology | ||||||
| 11/14/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | Cash or cash equivalent | $90.00 | General |
| Category: Oncology | ||||||
| 11/14/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Travel and Lodging | Cash or cash equivalent | $39.00 | General |
| Category: Oncology | ||||||
| 11/11/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,909.00 | General |
| Category: Oncology | ||||||
| 11/07/2024 | PFIZER INC. | ELREXFIO (Drug) | Food and Beverage | In-kind items and services | $59.91 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2024 | PFIZER INC. | ELREXFIO (Drug) | Travel and Lodging | In-kind items and services | $361.07 | General |
| Category: ONCOLOGY | ||||||
| 11/04/2024 | PFIZER INC. | ELREXFIO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,125.00 | General |
| Category: ONCOLOGY | ||||||
| 11/04/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,909.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ISB 1342-101 | Ichnos Sciences Inc. | $26,700 | 2 |
| PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | Regeneron Pharmaceuticals, Inc. | $4,613 | 15 |
| MEDI4736-MM-002 | Celgene Corporation | $2,559 | 1 |
| A Phase 1b Study of SAR650984 (Anti-CD38 mAb) in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM) | GENZYME CORPORATION | $2,500 | 2 |
| Final results of a Phase Ib study of isatuximab (ISA) plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM) | SANOFI-AVENTIS U.S. LLC | $1,323 | 2 |
| Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38 Hematological Malignancies | GENZYME CORPORATION | $1,051 | 3 |
| A Phase Ib study of isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma | SANOFI-AVENTIS U.S. LLC | $972.40 | 2 |
| A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma (CC-93269-MM-001) | Celgene Corporation | $935.00 | 1 |
| PCYC-1140-IM | Pharmacyclics LLC, An AbbVie Company | $915.43 | 3 |
| A Phase 1b Study of SAR650984 (Anti-CD38 mAb) in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed-Refractory Multiple Myeloma (RRMM) | GENZYME CORPORATION | $670.00 | 1 |
| A Phase 1b Study of SAR650984 (Anti-CD38 mAb) in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM) | SANOFI-AVENTIS U.S. LLC | $473.73 | 1 |
| Final results of a Phase Ib study of isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma | SANOFI-AVENTIS U.S. LLC | $450.39 | 1 |
| ACE-MM-200 | Celgene Corporation | $417.00 | 1 |
| MEDI4736-MM-003 | Celgene Corporation | $417.00 | 1 |
| A Phase 1b Study of SAR650984 (Isatuximab) in Combination With Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma | SANOFI-AVENTIS U.S. LLC | $316.49 | 1 |
| A phase 1b Study SAR650984 (Anti-CD38 mAb) in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed Refractory Multiple Myeloma (RRMM) | GENZYME CORPORATION | $265.00 | 1 |
| Isatuximab + Pomalidomide & Dexamethasone combination study | SANOFI-AVENTIS U.S. LLC | $158.16 | 1 |
| Phase 1 2 FIH Study of REGN5458 Anti-BCMA x Anti-CD3 Bispecific Antibody in Patients With Relapsed or Refractory Multiple Myeloma | Regeneron Pharmaceuticals, Inc. | $135.00 | 1 |
| Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies | GENZYME CORPORATION | $129.92 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 111 | 296 | $19,694 | $5,950 |
| 2021 | 6 | 193 | 312 | $94,787 | $30,742 |
| 2020 | 5 | 163 | 297 | $97,151 | $26,208 |
Total Patients
467
Total Services
905
Medicare Billing
$62,901
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 22 | 33 | $10,626 | $3,464 | 32.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 20 | 25 | $3,750 | $1,229 | 32.8% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 21 | 38 | $1,976 | $457.48 | 23.2% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 13 | 18 | $1,350 | $404.94 | 30.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 21 | 34 | $1,768 | $380.82 | 21.5% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 14 | 148 | $224.00 | $14.00 | 6.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 80 | 154 | $38,654 | $12,779 | 33.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 47 | 84 | $29,568 | $9,782 | 33.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 28 | 28 | $13,188 | $4,529 | 34.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 13 | 20 | $5,980 | $1,574 | 26.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 13 | 13 | $4,875 | $1,547 | 31.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 12 | 13 | $2,522 | $531.42 | 21.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 75 | 201 | $67,335 | $18,019 | 26.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 32 | 36 | $8,604 | $2,346 | 27.3% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 16 | 16 | $7,184 | $2,259 | 31.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 24 | 28 | $8,316 | $1,804 | 21.7% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 16 | 16 | $5,712 | $1,780 | 31.2% |
About Dr. William Bensinger, MD
Dr. William Bensinger, MD is a Internal Medicine healthcare provider based in Lakewood, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1922198886.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. William Bensinger, MD has received a total of $1.8M in payments from pharmaceutical and medical device companies, with $238,917 received in 2024. These payments were reported across 1,482 transactions from 27 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.4M).
As a Medicare-enrolled provider, Bensinger has provided services to 467 Medicare beneficiaries, totaling 905 services with total Medicare billing of $62,901. Data is available for 3 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology, Medical Oncology
- Location Lakewood, WA
- Active Since 10/13/2006
- Last Updated 10/05/2022
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1922198886
Products in Payments
- DARZALEX (Biological) $341,247
- SARCLISA (Biological) $253,005
- Revlimid (Drug) $199,406
- NINLARO (Drug) $193,159
- Kyprolis (Biological) $190,346
- CALQUENCE (Drug) $96,343
- Kyprolis (Drug) $95,224
- Pomalyst (Drug) $87,001
- ELREXFIO (Drug) $67,379
- CD38 (Drug) $12,214
- ABECMA (Biological) $10,078
- BLENREP (Biological) $9,200
- Venclexta (Biological) $7,872
- Durvalumab (Drug) $2,976
- EMPLICITI (Biological) $2,382
- FARYDAK (Drug) $1,500
- CC-93269 (Drug) $935.00
- Ibrutinib (Drug) $915.43
- SARCLISA (Drug) $850.36
- BESPONSA (Biological) $757.46
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Lakewood
Dr. Howard Uderman, M.d, M.D
Internal Medicine — Payments: $947,366
Internal Medicine $947,366
Dr. Kenneth Cohen, M.d, M.D
Internal Medicine — Payments: $269,079
Internal Medicine $269,079
Omkar Marathe, Md, MD
Internal Medicine — Payments: $41,508
Internal Medicine $41,508
Joseph Morelos, D.o, D.O
Internal Medicine — Payments: $32,524
Internal Medicine $32,524
Sarah Easaw, Md Llc, MD LLC
Internal Medicine — Payments: $28,719
Internal Medicine $28,719
Dr. Norman Gray, Md, MD
Internal Medicine — Payments: $17,345
Internal Medicine $17,345